The Golgi Apparatus Emerges as a Hidden Driver of Alzheimer’s Disease

For decades, Alzheimer’s disease research has fixated on two notorious culprits: the amyloid-beta plaques that clog the spaces between neurons and the tau tangles that strangle them from within. Now, a comprehensive review published in Experimental & Molecular Medicine argues that scientists have been overlooking a far less glamorous accomplice hiding in plain sight inside every neuron: the Golgi apparatus, the organelle that serves as the cell’s postal sorting office. According to authors Jaehoon Song, Seung-Jae Lee, and Inhee Mook-Jung of Seoul National University College of Medicine, an accumulating body of human genetic, proteomic, and lipidomic evidence points to the Golgi as a potential mechanistic hub of the disease, and possibly a promising new target for therapy.

The Golgi apparatus is best known as the processing and dispatch center of the secretory pathway. Proteins manufactured in the endoplasmic reticulum pass through its stacked membrane cisternae, where they are chemically modified, most notably through glycosylation, the attachment of sugar chains, and then sorted to their correct destinations, whether the plasma membrane, secretory vesicles, or lysosomes. The organelle also manufactures key lipids such as sphingomyelin and glycosphingolipids, participates in autophagosome formation, and runs its own quality-control degradation pathways. In other words, the Golgi sits at the crossroads of protein and lipid homeostasis, which is precisely why its failure could ripple through nearly every cellular process implicated in neurodegeneration.

That failure is not hypothetical. Postmortem studies of Alzheimer’s brains have long revealed fragmented, atrophied Golgi structures in affected neurons. More strikingly, when researchers expressed the amyloid precursor protein Swedish mutant in cells, the Golgi fragmented, and restoring Golgi architecture by expressing the structural proteins GRASP65 and GRASP55 dramatically reduced amyloid-beta production. In induced pluripotent stem cell-derived neurons from patients with sporadic Alzheimer’s disease, the fragmented Golgi phenotype persisted and, crucially, appeared before amyloid and tau pathology developed, suggesting that Golgi breakdown may be one of the earliest cellular events in the disease rather than a late consequence of it.

The strongest new argument for the Golgi’s relevance comes from large-scale human data. When the authors surveyed genetic studies, a striking pattern emerged: multiple independent analyses keep nominating Golgi-related genes as Alzheimer’s risk factors. An RNA-sequencing analysis found that Golgi-related gene ontology terms were elevated both in patients and in people with high polygenic risk scores for the disease, particularly in the temporal cortex. An X-chromosome-wide association study identified SLC9A7, a sodium/proton exchanger concentrated in the trans-Golgi network that maintains the organelle’s acidity, as the only genome-wide significant risk locus. Because Golgi luminal pH governs protein modification, glycosylation, and trafficking, its disruption could derail amyloid precursor protein processing among many other consequences.

Other risk genes reinforce the same theme. SORL1 and SORCS1, both well-established genetic risk factors, encode sortilin-family receptors that shepherd the amyloid precursor protein back to the trans-Golgi network, keeping it away from the endosomes where amyloidogenic cleavage predominates. Adaptor protein 4 complex genes AP4M1 and AP4E1, flagged by enhancer mapping of genome-wide association loci, regulate the precursor protein’s delivery to endosomes. A protective variant in NSF, a gene essential for Golgi reassembly and vesicle fusion, was identified in whole-exome sequencing of patients lacking the ApoE4 allele, hinting that Golgi integrity itself may confer resilience. Machine learning analysis of European GWAS data proposed COG7, a subunit of the complex that maintains Golgi structure and glycosylation, as a new risk gene, and multiancestry proteomic analyses independently nominated COG7, the trans-Golgi metalloprotease CPD, and the retrograde trafficking proteins SNX1, SNX32, and STX6 as candidate causal proteins.

Proteomics adds a second layer of evidence. A landmark 2022 study of more than 500 human brain samples found that Golgi and protein transport module signatures were reduced in asymptomatic Alzheimer’s brains and diminished further in symptomatic cases, correlating with cognitive scores. Perhaps most intriguingly, the extracellular matrix protein repertoire, the matrisome, showed the most prominent proteomic changes in the disease that were invisible at the RNA level, implying that post-translational modifications are the real driver. Since matrix proteins such as proteoglycans and collagen are extensively processed and glycosylated within the Golgi before secretion, Golgi dysfunction offers a mechanistically coherent explanation for this transcriptome-proteome discordance, and matrisome proteins are known to colocalize with amyloid plaques.

A 2024 glycomics study sharpened the picture further by mapping the N-glycan landscape of Alzheimer’s brains. The most altered sugar structures, sialylated and highly branched forms, are built inside the Golgi, and the affected glycoproteins clustered at synapses and the cell surface. Glycoform signatures tied to disease status involved L1CAM and NPTX1, markers of synaptic plasticity and synaptic loss, as well as ATP1B1, a subunit of the sodium-potassium pump essential for neural signaling. Expression of several Golgi-resident glycosylation enzymes, including MAN2A1, MGAT1, and members of the B3GALT, B4GALT, ST6GAL, and ST8SIA families, was altered across multiple brain regions, consistent with a systematic breakdown of Golgi-dependent protein modification that could directly undermine synapses.

Lipid biology supplies a third pillar. The Golgi is the primary site of ceramide processing through glucosylceramide synthase, whose levels fall in Alzheimer’s brains in correlation with ceramide accumulation, a lipid that promotes amyloid-beta production, oxidative stress, and neuronal death. The Golgi-localized enzyme neutral sphingomyelinase 2 drives the secretion of extracellular vesicles that can spread pathological tau between cells; inhibiting it reduced tau propagation and neurodegeneration in mouse models, and neuronal deletion of the gene reduced amyloid-beta production. Meanwhile, the oxysterol-binding protein OSBP1, which exchanges cholesterol and PI4P between the trans-Golgi network and the endoplasmic reticulum at membrane contact sites, regulates cholesterol distribution, mitochondrial fission, and retrograde trafficking, and its knockdown increased amyloidogenic processing of the amyloid precursor protein, linking Golgi-managed cholesterol homeostasis directly to plaque biology.

The authors synthesize these threads into four candidate pathogenic mechanisms. First, Golgi fragmentation may disrupt the normal segregation of the amyloid precursor protein and its processing enzymes, increasing their contact and boosting amyloid-beta generation, possibly even within the Golgi itself. Second, impaired trafficking between the Golgi and the endolysosomal system would trap the precursor protein in endosomes while starving lysosomes of properly sorted enzymes, simultaneously raising amyloid production and lowering its clearance. Third, defective glycosylation would alter countless proteins, including the amyloid precursor protein itself, whose O-glycosylation influences its trafficking and cleavage. Fourth, lipid dyshomeostasis would feed back on Golgi membrane integrity, creating a self-reinforcing vicious cycle that also damages mitochondria and the endoplasmic reticulum. Upstream triggers, including aging, DNA damage, oxidative stress, and neuronal hyperexcitability, as well as amyloid-beta and tau themselves, can all induce Golgi fragmentation, closing the loop.

Therapeutically, the possibilities are still largely conceptual but tantalizing. Restoring Golgi structural integrity, for example through nonphosphorylatable GRASP55/65 variants, could in principle ameliorate multiple disease processes at once. More targeted options include nSMase2 inhibitors, which have already shown benefits in Alzheimer’s mouse models; overexpression of SORL1, which redirects the amyloid precursor protein to the Golgi and lowers amyloid-beta output; and reinforcement of glycosylation or lipid balance through COG7, glucosylceramide synthase, or OSBP1. The authors are candid about the caveats: causality between Golgi dysfunction and Alzheimer’s pathogenesis has not been rigorously established, most evidence comes from familial disease models rather than the sporadic form that accounts for roughly 90 percent of cases, and because the Golgi handles so much cellular traffic, interventions could carry pleiotropic side effects. Still, with anti-amyloid antibodies delivering only modest clinical benefit, the review makes a compelling case that keeping this cellular post office running smoothly may be one of the most underexplored strategies for halting the disease, and that the humble Golgi apparatus deserves a central seat at the Alzheimer’s research table.

Subject of Research: The role of Golgi apparatus dysfunction in Alzheimer's disease pathogenesis and therapy

Article Title: Golgi dysfunction in Alzheimer disease: from human multiomic signatures to therapeutic targets

Article References: Song, J., Lee, S.-J., & Mook-Jung, I. (2026). Golgi dysfunction in Alzheimer disease: from human multiomic signatures to therapeutic targets. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01851-8

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01851-8

Keywords: Alzheimer's disease, Golgi apparatus, amyloid-beta, tau, glycosylation, lipid metabolism, SORL1, trans-Golgi network, multiomics, neurodegeneration, endolysosomal trafficking, therapeutic targets